|
|
Blood, 1 June 2007, Vol. 109, No. 11, pp. 4810-4815.
Prepublished online as a Blood First Edition Paper on February 20, 2007; DOI 10.1182/blood-2006-11-057216.
 Previous Article | Next Article 
Submitted November 17, 2006
Accepted February 13, 2007
Eradication of lymphoma by CD8 T cells following anti-CD40 monoclonal antibody therapy is critically dependent on CD27 costimulation
Ruth R French, Vadim Y Taraban, Graham R Crowther, Tania F Rowley, Juliet C Gray, Peter W Johnson, Alison L Tutt, Aymen Al-Shamkhani, and Martin J Glennie*
Tenovus Research Laboratory, Cancer Sciences Division, School of Medicine, University General Hospital, Southampton, United Kingdom
* Corresponding author; email: mjg{at}soton.ac.uk.
Growing evidence points to the potential of agonistic anti-CD40 mAb as adjuvants for vaccination against cancer. These appear to act by maturing DC and allowing them to prime CD8 cytotoxic T lymphocytes (CTL). While it is well established that optimal T-cell priming requires co-stimulation via B7:CD28, recent studies emphasize the contribution of TNF receptors to this process. To understand how anti-CD40 mAb triggers effective anti-tumor immunity we investigated the role of TNFR superfamily members CD27 and 4-1BB in the generation of this immunity and showed that, while partially dependent on 4-1BB:4-1BBL engagement, it is completely reliant on CD27:CD70 interactions. Importantly, blocking CD70, and to some extent 4-1BBL, during anti-CD40 treatment, prevented accumulation of tumor reactive T cells and subsequent tumor protection. However, it did not influence changes in DC number, phenotype, nor the activity of CTL once immunity was established. We conclude that CD27:CD70 and 4-1BB:4-1BBL interactions are needed for DC-driven accumulation of anti-tumor CTL following anti-CD40 mAb treatment. Finally, in support of the critical role for CD70:CD27, we show for the first time that agonistic anti-CD27 mAb given without a DC maturation signal completely protect tumor-bearing mice and provides a highly potent reagent for boosting anti-tumor T cell immunity.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Hashimoto-Okada, T. Kitawaki, N. Kadowaki, S. Iwata, C. Morimoto, T. Hori, and T. Uchiyama
The CD70-CD27 interaction during the stimulation with dendritic cells promotes naive CD4+ T cells to develop into T cells producing a broad array of immunostimulatory cytokines in humans
Int. Immunol.,
August 1, 2009;
21(8):
891 - 904.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Zhao, A. Song, R. Haque, F. Lei, L. Weiler, X. Xiong, Y. Wu, M. Croft, and J. Song
Cooperation between Molecular Targets of Costimulation in Promoting T Cell Persistence and Tumor Regression
J. Immunol.,
June 1, 2009;
182(11):
6744 - 6752.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. M. Keller, Y. Xiao, V. Peperzak, S. H. Naik, and J. Borst
Costimulatory ligand CD70 allows induction of CD8+ T-cell immunity by immature dendritic cells in a vaccination setting
Blood,
May 21, 2009;
113(21):
5167 - 5175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zhang, Z. Yao, S. Dubois, W. Ju, J. R. Muller, and T. A. Waldmann
Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer
PNAS,
May 5, 2009;
106(18):
7513 - 7518.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. P. J. M. van Gisbergen, R. W. van Olffen, J. van Beek, K. F. van der Sluijs, R. Arens, M. A. Nolte, and R. A. van Lier
Protective CD8 T Cell Memory Is Impaired during Chronic CD70-Driven Costimulation
J. Immunol.,
May 1, 2009;
182(9):
5352 - 5362.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. J. Kraus, J. S. Haring, and G. A. Bishop
TNF Receptor-Associated Factor 5 Is Required for Optimal T Cell Expansion and Survival in Response to Infection
J. Immunol.,
December 1, 2008;
181(11):
7800 - 7809.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Kim, K. Park, H. J. Kim, J. Kim, H.-A Kim, D. Jung, H. J. Kim, H.-J. Choi, S.-Y. Choi, K. W. Seo, et al.
Breaking of CD8+ T Cell Tolerance through In Vivo Ligation of CD40 Results in Inhibition of Chronic Graft-versus-Host Disease and Complete Donor Cell Engraftment
J. Immunol.,
November 15, 2008;
181(10):
7380 - 7389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L-L. Chiang, J. A. Ledermann, E. Aitkens, E. Benjamin, D. R. Katz, and B. M. Chain
Oxidation of Ovarian Epithelial Cancer Cells by Hypochlorous Acid Enhances Immunogenicity and Stimulates T Cells that Recognize Autologous Primary Tumor
Clin. Cancer Res.,
August 1, 2008;
14(15):
4898 - 4907.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Skibola, A. Nieters, P. M. Bracci, J. D. Curry, L. Agana, D. R. Skibola, A. Hubbard, N. Becker, M. T. Smith, and E. A. Holly
A functional TNFRSF5 gene variant is associated with risk of lymphoma
Blood,
April 15, 2008;
111(8):
4348 - 4354.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Y. Taraban, S. Martin, K. E. Attfield, M. J. Glennie, T. Elliott, D. Elewaut, S. Van Calenbergh, B. Linclau, and A. Al-Shamkhani
Invariant NKT Cells Promote CD8+ Cytotoxic T Cell Responses by Inducing CD70 Expression on Dendritic Cells
J. Immunol.,
April 1, 2008;
180(7):
4615 - 4620.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Kretz-Rommel, F. Qin, N. Dakappagari, R. Cofiell, S. J. Faas, and K. S. Bowdish
Blockade of CD200 in the Presence or Absence of Antibody Effector Function: Implications for Anti-CD200 Therapy
J. Immunol.,
January 15, 2008;
180(2):
699 - 705.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
